Efficacy of Lactococcus lactis 11/19-B1 in a Mouse Model of Allergic Rhinitis
International Archives of Otorhinolaryngology · 01.07.2026 · 30 (03) · 001-007
DOI: 10.1055/a-2804-6274 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Archives of Otorhinolaryngology, erschienen am 01.07.2026. Verfasst von Toshihiko Suzuki und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Fukushima Medical University Aizu Medical Center, Fukushima, Japan. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Lactococcus lactis (L. lactis) is widely used in fermented foods and has immunomodulatory properties. However, its effects on allergic rhinitis remain unclear.
Objective
This study evaluated the efficacy of L. lactis 11/19-B1 in mitigating allergic rhinitis symptoms in a mouse model.
Methods
Female BALB/c mice were fed a diet supplemented with heat-killed L. lactis 11/19-B1, while allergic rhinitis was induced via intraperitoneal and intranasal administration of ovalbumin (OVA). The positive control group received a standard diet without L. lactis 11/19-B1. Sneezing frequency was recorded, and tissue samples were collected for analysis. Serum OVA-immunoglobulin E (IgE) levels were also measured, nasal mucosa histopathology assessed, and the interleukin 4 (IL-4), interferon gamma (IFN-γ), T helper (Th) 1/Th2 balance in cluster of differentiation (CD) 4+ T cells analyzed by flow cytometry (FCM).
Results
Mice receiving L. lactis 11/19-B1 showed significantly reduced sneezing frequency and decreased eosinophil infiltration in the nasal mucosa. No significant changes in serum OVA-IgE levels were observed. Flow cytometry analysis showed a significant increase in the Th1/Th2 ratio in Peyer's patches in the L. lactis 11/19-B1 group compared with the positive control group.
Conclusion
These findings suggest that L. lactis 11/19-B1 alleviates allergic rhinitis symptoms by modulating the Th1/Th2 balance and reducing eosinophil infiltration, independently of IgE suppression. These findings highlight its potential as a dietary supplement for allergic disease management .
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology, Fukushima Medical University Aizu Medical Center, Fukushima, Japan.
- Department of Microbiology, Fukushima Medical University, Fukushima, Japan.
- Department of Otorhinolaryngology, International University of Health and Welfare School of Medicine, Narita, Japan.
- Ohara General Hospital, Fukushima, Japan.
ORCID-Profile: Toshihiko Suzuki
Zitieren
APA
Suzuki, T., Miyazaki, N., Ozaki, C., Okano, M., Ogawa, H., & Suzutani, T. (2026). Efficacy of Lactococcus lactis 11/19-B1 in a Mouse Model of Allergic Rhinitis. International Archives of Otorhinolaryngology, 30(03), 001-007. https://doi.org/10.1055/a-2804-6274
Vancouver
Suzuki T, Miyazaki N, Ozaki C, Okano M, Ogawa H, Suzutani T. Efficacy of Lactococcus lactis 11/19-B1 in a Mouse Model of Allergic Rhinitis. International Archives of Otorhinolaryngology. 2026;30(03):001-007. doi:10.1055/a-2804-6274
BibTeX
@article{Suzuki2026,
author = {Suzuki, Toshihiko and Miyazaki, Nozomu and Ozaki, Chiaki and Okano, Mitsuhiro and Ogawa, Hiroshi and Suzutani, Tatsuo},
title = {Efficacy of Lactococcus lactis 11/19-B1 in a Mouse Model of Allergic Rhinitis},
journal = {International Archives of Otorhinolaryngology},
year = {2026},
volume = {30},
number = {03},
pages = {001--007},
doi = {10.1055/a-2804-6274}
}
EUVIMED